A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems related to COVID-19, thanks to a $1.5 million grant from the federal government to be released June 1.


Chrysalin, or TP508, a regenerative thrombin peptide developed by scientist Darrell Carney, has been tested in human clinical trials for skin and bone tissue repair and, in preclinical studies, has demonstrated the ability to mitigate effects of radiation and traumatic brain injury.

Now, the drug will be tested for use against the cardiovascular problems doctors are finding in some COVID-19 patients, said Carney, CEO and president of Chrysalis BioTherapeutics and principal developer of the drug.

Read more.